Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers.

Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers R. Stupp, A. F. Hottinger, M. J. van den Bent, P.-Y. Dietrich & A. A. Brandes Centre Hospitalier Universitaire Vaudois and University of Lausanne; Hopitaux Universitaire Genevois and University of Geneva, Switzerland; Erasmus University/Daniel de Hoed Cancer Center, Rotterdam, The Netherlands; Bellaria-Maggiore Hospital, Azienda USL of Bologna, Bologna, Italy

[1]  J. Uhm.  MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients , 2009 .

[2]  H. Heinzl,et al.  Anti‐O6‐Methylguanine‐Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker * , 2008, Brain pathology.

[3]  A. Brandes,et al.  Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. , 2008, Neuro-oncology.

[4]  Dieta Brandsma,et al.  Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. , 2008, The Lancet. Oncology.

[5]  Mark R Gilbert,et al.  Chemoradiotherapy in malignant glioma: standard of care and future directions. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Stupp,et al.  Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (GBM) , 2007 .

[7]  M. Bent,et al.  The incidence of pseudo-progression in a cohort of malignant glioma patients treated with chemo-radiation with temozolomide , 2007 .

[8]  W. Mason,et al.  Canadian recommendations for the treatment of glioblastoma multiforme , 2007, Current oncology.

[9]  R. Stupp,et al.  Integrin inhibitors reaching the clinic. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  T. Mikkelsen,et al.  Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Stupp,et al.  Methylguanine methyltransferase testing in glioblastoma: when and how? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Gallo,et al.  Preclinical Pharmacokinetic and Pharmacodynamic Evaluation of Metronomic and Conventional Temozolomide Dosing Regimens , 2007, Journal of Pharmacology and Experimental Therapeutics.

[13]  Andrew E. Sloan,et al.  Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma , 2007, Journal of Neuro-Oncology.

[14]  E. Shaw,et al.  A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. , 2006, Cancer research.

[15]  A. Brandes,et al.  Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO) , 2006, British Journal of Cancer.

[16]  P. Burger,et al.  Identification of der(1;19)(q10;p10) in Five Oligodendrogliomas Suggests Mechanism of Concurrent 1p and 19q Loss , 2006, Journal of neuropathology and experimental neurology.

[17]  R. Stupp,et al.  Temozolomide: a milestone in neuro-oncology and beyond? , 2006, Expert review of anticancer therapy.

[18]  Walter Curran,et al.  Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Denis Lacombe,et al.  Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Stupp,et al.  Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide , 2006, Nature Clinical Practice Oncology.

[21]  D. Bigner,et al.  Recent advances in the treatment of malignant astrocytoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Michael Weller,et al.  Changing paradigms--an update on the multidisciplinary management of malignant glioma. , 2006, The oncologist.

[23]  D. Misailidou,et al.  Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[25]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[26]  M. J. van den Bent,et al.  Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression , 2004, Neurology.

[27]  J. Dichgans,et al.  One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma , 2004, Neurology.

[28]  Luca Regli,et al.  Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide , 2004, Clinical Cancer Research.

[29]  K. Sepkowitz,et al.  Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  S. Grossman,et al.  Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumors , 2003, Journal of Neuro-Oncology.

[31]  E. Raymond,et al.  Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  S. Grossman,et al.  Low CD4 counts and PCP prophylaxis in patients with primary brain tumors treated with steroids and radiation , 2003 .

[33]  C. Vecht,et al.  Interactions between antiepileptic and chemotherapeutic drugs , 2003, The Lancet Neurology.

[34]  A. Tolcher,et al.  Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules , 2003, British Journal of Cancer.

[35]  R. Stupp,et al.  New drugs and combinations for malignant glioma. , 2003, Forum.

[36]  J. Dichgans,et al.  Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. , 2002, Cancer research.

[37]  Reto Meuli,et al.  Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  R A Betensky,et al.  Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  M. Berger,et al.  p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. , 2001, Cancer research.

[40]  M Brada,et al.  Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  David M. Thomas,et al.  Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[43]  D. Osoba,et al.  A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse , 2000, British Journal of Cancer.

[44]  J. Heimans,et al.  Survival of human glioma cells treated with various combination of temozolomide and X-rays. , 2000, International journal of radiation oncology, biology, physics.

[45]  L. Recht,et al.  Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors , 2000, Neurology.

[46]  J. Kovacs,et al.  Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. , 2000, The New England journal of medicine.

[47]  Susan M. Chang,et al.  Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  R. McLendon,et al.  DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  H. Eyre,et al.  Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  M. Roddie,et al.  Phase I trial of temozolomide using an extended continuous oral schedule. , 1998, Cancer research.

[51]  E. Newlands,et al.  O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU. , 1996, British Journal of Cancer.

[52]  B. Scheithauer,et al.  Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  F. Laval,et al.  Enhancement of O6-methylguanine-DNA-methyltransferase activity induced by various treatments in mammalian cells. , 1986, Cancer research.